P
Philip Belitsky
Researcher at Queen Elizabeth II Health Sciences Centre
Publications - 57
Citations - 3387
Philip Belitsky is an academic researcher from Queen Elizabeth II Health Sciences Centre. The author has contributed to research in topics: Transplantation & Kidney. The author has an hindex of 25, co-authored 57 publications receiving 3343 citations. Previous affiliations of Philip Belitsky include Dalhousie University & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
Paul Keown,Pekka Häyry,Peter J. Morris,Calvin R. Stiller,Christopher M. Barker,Lisa Carr,David Landsberg,Ian R. Hardie,Russell J. Rigby,Helena Isoniemi,Derek W. R. Gray,Philip Belitsky,Allan McDonald,Tim Mathew,A. Clarkson,L. Barratt,B. Buchholz,Rowan Walker,Günther Kirste,Norman Muirhead,David J. Tiller,Geoff Duggin,Philip F. Halloran,Pierre Daloze,Gilles St. Louis,David Russell,David Ludwin,P. Vialtel,U. Binswanger,J. A C Buckels,Jean Louis Touraine,David P. Hickey,Giuseppe Remuzzi,Giuseppe Locatelli,F. T. Lam,Ed Tapper +35 more
TL;DR: MMF is associated with a significantly lower rate of treatment failure compared with AZA during the first 6 months after renal transplantation and produces a clinically important reduction in the incidence, severity, and treatment of acute graft rejection.
Journal ArticleDOI
Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
TL;DR: The data suggest that a target AUC0-12 of 9500-11500 or AUC1-4 of 4400-5500 microg x h/L may provide optimal Neoral immunosuppression and early AUC based on PK0-4 is more closely associated with AR and CsANT than is C0.
Journal ArticleDOI
The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants.
TL;DR: Patients free of rejection and with stable renal function continued to do well on maintenance CsA monotherapy, and they were more likely to be on Cs a monotherapy than those with rejection episodes (P less than 0.01).
Journal ArticleDOI
Approaching the Therapeutic Window for Cyclosporine in Kidney Transplantation: A Prospective Study
Kamran Mahalati,Philip Belitsky,Kenneth A. West,Bryce A. Kiberd,Albert D. Fraser,Ingrid S. Sketris,A. S. MacDonald,Vivian C. McAlister,Joseph Lawen +8 more
TL;DR: Attainment of a target range of 4400 to 5500 microg/h per L for AUC(0-4) early after transplantation has been demonstrated to reduce significantly the risk of AR and CyANT.
Journal ArticleDOI
Is routine ureteric stenting needed in kidney transplantation? A randomized trial.
Javier Dominguez,Catherine M. Clase,Kamran Mahalati,Allan S. MacDonald,Vivian C. McAlister,Philip Belitsky,Bryce A. Kiberd,Joseph Lawen +7 more
TL;DR: Routine ureteric stenting is unnecessary in kidney transplantation in patients at low risk for urological complications, and careful surgical technique with selective stenting of problematic anastomoses yields similar results.